In summary, the present study is the first to demonstrate that treatment with the S1PR2 antagonist (JTE013) enhanced TGFβ/Smad and Akt signaling and increased VEGFA, PDGFA, and GDF15 gene expressions in murine BMSCs with or without bacterial infection. The gene discussed is AKT1; the disease is bacterial infectious disease.